Significance of overexpression of metallothionein in mouse urinary bladder focal lesions induced by treatment with N-butyl-N-(4-hydroxybutyl)- nitrosamine

Cancer Science

Volumn 94, Issue 12, 2003, Pages 1052-1058

  Mitsuhashi, Makoto ^a   Wanibuchi, Hideki ^a   Morimura, Keiichirou ^a   Doi, Ken'ichiro ^a   Wei, Min ^a   Wada, Seiji ^a   Nakatani, Tatsuya ^a   Fukushima, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; METALLOTHIONEIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER MUCOSA; BODY WEIGHT; CANCER CLASSIFICATION; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

ANIMALS; APOPTOSIS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; IMMUNOHISTOCHEMISTRY; MALE; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0346399570     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01400.x     Document Type: Article

References (46)

1. Banerjee D, Onosaka S, Cherian MG. Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of rat liver and kidney. Toxicology 1982; 24: 95-105.
2. Coyle P, Philcox JC, Rofe AM. Methallothionein induction in cultured rat hepatocytes by arthritic rat serum, activated macrophages, interleukin-6, interleukin-11 and leukemia inhibitory factor. Inflamm Res 1995; 44: 475-81.
3. Cherian MG, Goyer RA. Metallothioneins and their role in the metabolism and toxicity of metals. Life Sci 1978; 23: 1-10.
4. Cherien MG, Huang PC, Klaassen CD, Liu Y-P, Longfellow DG, Waalkes MP. National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis. Cancer Res 1993; 53: 922-5.
5. Lohrer H, Robson T. Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 2000; 10: 2279-84.
6. Miura T, Muraoka S, Ogiso T. Antioxidant activity of metallothionein compared with reduced glutathione. Life Sci 1997; 60: 301-9.
7. Abel J, de Ruiter N. Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. Toxicol Lett 1989; 47: 191-6.
8. Kagi JH, Schaffer A. Biochemistry of metallothionein. Biochemistry 1988; 27: 8509-15.
9. Jayasurya A, Bay BH, Yap WN, Tan NG, Tan BKH. Proliferative potential in nasopharyngeal carcinoma; correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 2000; 21: 1809-12.
10. Markant A, Pallauf J. Metallothionein and zinc as potential antioxidants in radical-induced lipid peroxidation in cultured hepatocytes. J Trace Elem Med Biol 1996; 10: 88-95.
11. Stennard FA, Holloway AF, Hamilton J, Weit A. Characterisation of six additional human metallothionein genes. Biochim Biophys Acta 1994; 1218: 357-65.
12. Cavigelli M, Kagi JH, Hunziker PE. Cell- and inducer-specific accretion of human isometallothioneins. Biochem J 1993; 292: 551-4.
13. Jahroudi N, Foster R, Price-Hanghey J, Beitel G, Gedamu L. Cell type specific and differential reguration of the human metallothionein genes. Correlation with DNA methylation and chronic structure. J Biol Chem 1990; 265: 6506-11.
14. Douglas-Jones AG, Schmid RW, Bier B, Horgan K, Lyons K, Dallimore ND. Metallothionein expression in duct carcinoma in situ of the breast. Hum Pathol 1995; 26: 217-22.
15. Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen B, Williams RD. Absence of immunohistochemical metallothionein staining in bladder tumour specimens predicts response to neoadjvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994; 152; 2272-5.
16. Nartey N, Cherian MG, Banerjee DI. Immunohistochemical localization of metallothionein in human testicular embryonal carcinoma cells. Virchows Archiv Pathol Anat Histopathol 1989; 45: 545-9.
17. Chaurin PJ, Cherian MG, Wysocki GP, Pringle GA. A comparison of metallothionein expression in human normal and neoplastic salivary gland tissue using immunohistochemistry. Toxicologist 1992; 12: 379.
18. Ohshio G, Imamura T, Okada N, Wang ZH, Yamaki K, Kyogoka T, Suwa H, Yamake H, Imamura M. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol 1996; 122: 351-5.
19. Giuffre G, Barresi G, Sturniolo GC, Sarnelli R, D'Luca R, Tuccavi G. Immunohistochemical expression of metallothionein in normal human colorectal mucosa in adenomas and in adenocarcinomas and their associated metastases. Histopathology 1996; 29: 347-54.
20. Onosaka S, Min KS, Fukuhara G, Tanaka K, Tashiro SI, Simizu I, Furuta M, Yasutomi T, Kobashi K, Yamamoto K. Concentration of metallothionein and metals in malignant and neomalignant tissues in human liver. Toxicology 1986; 38: 261-8.
21. Ito N. Early changes caused by N-butyl-N-(4-hydroxybutyl)nitrosamine. Gann Monogr 1975; 17: 367-81.
22. Fukushima S, Murasaki G, Hirose M, Nakanishi K, Hasegawa R, Ito N. Histopathological analysis of preneoplastic changes of during N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Acta Pathol Jpn 1982; 32: 243-50.
23. Cohen SM, Jacobs JB, Arai M, Johansson S, Friedell GH. Early lesions in experimental bladder cancer: experimental design and light microscopic findings. Cancer Res 1976; 36: 2508-11.
24. 1 mice. Jpn J Cancer Res 1991; 82: 650-6.
25. Sega Y, Hashimoto H, Yachiku S, Tokumitsu M, Kaneko S. Immunohistochemical expression of metallothionein in histopathological parameters and patient survival. J Urol 2002; 168: 2227-31.
26. Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD. Abscence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994; 152: 2272-5.
27. Cai L, Wang GJ, Xu ZL, Deng DX, Chakrabarti S, Cherian MG. Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC)from Northern China. Anticancer Res 1998; 18: 4667-72.
28. Takaba K, Saeki K, Suzuki K, Wanibuchi H, Fukushima S. Significant overexpression of metallothionein and cyclin D1 and apoptosis in the early process of rat urinary bladder carcinogevesis induced by treatment with N-butyl-N-(4-hydroxybutyl)nitrosamine or sodium L-ascorbate. Carcinogenesis 2000; 21: 691-700.
29. Abdel-Mageed A, Agrawal KC. Antisense down-reguration of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 1997; 4: 199-207.
30. Jin R, Chow VTK, Tan PH, Dheen ST, Duan W, Bay BH. Methallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002; 23: 81-6.
31. White E. Life, death and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.
32. Uren AG, Vaux DL. Molecular and clinical aspects of apoptosis. Pharmacol Ther 1996; 72: 37-50.
33. Sundermann F. The influence of zinc on apoptosis. Ann Clin Lab Sci 1995; 25: 134-42.
34. Fraker PJ, Telford WG. A reappraisal of the role of zinc in life and death decisions of cells. Proc Soc Exp Biol Med 1997; 215: 229-36.
35. Deng DX, Chakraberti S, Waalkes MP, Cherian MG. Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic carcinoma. Histopathology 1998; 32: 348-55.
36. Penkowa M, Hidalgo J. Metallothionein treatment reduces proinflammatory cytokines IL-6 and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp Neurol 2001; 170: 1-14.
37. Kontozoglon TE, Banerjee DI, Cherian MG. Immunohistochemical localization of metallothionein in human testicular embryonal carcinoma cells. Virchows Arch A Pathol Anat Histopathol 1989; 415: 545-9.
38. Chin JL, Banerjee DI, Kadhim SA, Kotazaglu T, Chauvant PT, Cherian MG. Metallothionein in testicular germ cell tumor and drug resistance. Clinical correlation. Cancer 1993; 72: 3029-35.
39. Onosaka S, Min KS, Fukuhara C, Tanaka K, Tashiro SI, Shimizu I, Furuta M, Yasutomi T, Kobishi K, Yamamoto KI. Concentrations of metallothionein and metals in malignant and non malignant tissues in human liver. Toxicology 1986; 38: 261-8.
40. Onosaka S, Tanaka K. Cd-Hem method and its application. In: Klaassen CD, Suzuki KT, editors. Metallothionein in biology and medicine. Boca Raton, FL: CRC Press; 1991. p. 1-11.
41. Cherian MG. The significance of the nuclear and cytoplasmic localization of metallothionein in human liver and tumor cells. Environ Health Perspect 1994; 102: 131-5.
42. Cherian MG, Howell SB, Imura N, Klaassen CD, Koropatnick J, Lazo JS, Waalkes M. Contemporary issues in toxicology. Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 1994; 126: 1-5.
43. Jasani B, Schmid KW. Significance of metallothionein overexpression in human tumours. Histopathology 1997; 31: 211-4.
44. Krauter B, Nagel W, Hartmann HJ, Weser U. Copper-thionein in melanoma. Biochim Biophys Acta 1989; 1013: 212-7.
45. Palmiter RD. The elusive function of metallothioneins. Proc Natl Acad Sci USA 1998; 95: 8428-30.
46. Kondo Y, Woo ES, Michalska AE, Choo KH, Lazo JS. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 1995; 55: 2021-3.